Skip to main content

Strengthening Capacity for Research for HIV-Associated Malignancies in Sub-Saharan Africa and Other Low- and Middle-Income Countries (LMICs)

Building capacity and sharing success stories in HIV-associated malignancy research at the 2019 U54 Consortia Annual Meeting in Dar es Salaam, Tanzania.

The brunt of the HIV epidemic is borne by Low- and Middle-Income Countries (LMICs), with sub-Saharan Africa being the epicenter of the epidemic. As people living with HIV are aging, LMICs are also facing a concomitant rise in the incidence of malignancies. Cancer rates in LMICs are affected by the higher burden and younger age of acquisition of oncogenic viruses (particularly human papillomavirus [HPV], Epstein Barr virus [EBV], Kaposi sarcoma-associated herpesvirus [KSHV], hepatitis B virus [HBV] and hepatitis C virus [HCV]) and behavioral risk factors. Also, these countries have health care systems that are poorly equipped to screen, diagnose and treat cancer. AIDS defining malignancies remain a significant problem; in some countries of East Africa, Kaposi sarcoma is among the most common cancers in men, even in with the expansion of antiretroviral therapy. 

NCI and the Fogarty International Center (FIC) have partnered in several efforts for developing research capacity in LMICs on HIV-associated cancers. Below is a list of the initiatives that have been developed to increase research capacity in LMICs:

  • Sub-Saharan African Collaborative HIV and Cancer Consortia (U54) RFA, (CA-13-010),  projects ended in 2020.
  • Collaborative Consortia for the Study of HIV-Associated Cancers: U.S. and Low-and Middle-Income Country Partnerships (U54) RFA, (CA-16-018), projects will end in 2022.
  • U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trials Optional) RFA, (CA-20-001), projects will end in 2025.

The newest initiative is the HIV-Associated Malignancy Research Centers (HAMRCS). The goals of the HAMRCS and the Collaborative Consortia for the Study of HIV-Associated Cancers are to provide an opportunity to conduct research on HIV-associated cancers that will increase our knowledge of the pathogenesis of cancer that are common in people living with HIV as well as provide data on early detection and treatment options. The knowledge gained will be of value to the LMICs and the U.S. Support research in the understanding of, prevention of, and treatment of HIV-associated cancers. The goals of the HAMRCS are:

  • Develop research capacity in LMICs with a significant burden of HIV-associated cancers.
  • Support collaborations between U.S. investigators and LMIC investigators.
  • Foster the development of early career investigators from the U.S. and LMICs interested in conducting research in HIV-associated cancers.

HIV-Associated Malignancy Research Centers (HAMRCs) (funded in FY 2020)

  • CA254571: United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related Cancers: University of California San Francisco/Uganda and Tanzania
  • CA254568: Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/Malignancies: Einstein/ Rwanda and Democratic Republic of Congo
  • CA254564: Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa: University of North Carolina Chapel Hill/Malawi and South Africa
  • CA254569: Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA): Baylor College of Medicine/Uganda/Malawi/Botswana
  • CA254518: The East Africa Consortium for HPV and Cervical Cancer in Women living with HIV/AIDS: Indiana University/Kenya and Uganda
  • CA254566: Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization, and imaging: Case Western Reserve University/Uganda and Tanzania
  • CA254565: HIV and HCC in Africa: The H2A Consortium: Johns Hopkins University/Uganda and Senegal

Collaborative Consortia for the Study of HIV-Associated Cancers (funded in FY 2017)

  • CA221204: The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP) University of Nebraska-Lincoln/Zambia
  • CA221205: Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria: Northwestern University/Nigeria
  • CA221208: UM CFAR SCCC Argentina Consortium for research and training in Virally Induced AIDS Malignancies UM CFAR SCCC Argentina Consortium for research and training in Virally Induced AIDS Malignancies: University of Miami/ Argentina 
     

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Strengthening Capacity for Research for HIV-Associated Malignancies in Sub-Saharan Africa and Other Low- and Middle-Income Countries (LMICs) was originally published by the National Cancer Institute.”